Doc Code:

PTO/SB/91 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and **CORRESPONDENCE ADDRESS** INDICATION FORM

Application Number	10/568,399
Filing Date	
First Named Inventor	Beswick et al.
Title	7-Azaindole Derivatives as COX2
Art Unit	
Examiner Name	
Attorney Docket Number	PB60121USW

I here	by revoke all p	oreviou	us powers of attorney given in the a	above-ide	entit	fied applicatio	n.	
I here	by appoint:	•						
X	Practitione	ctitioners associated with the Customer Number		r:	23347			
	OR							
	Practitione	er(s) na	amed below:					
		Name			Registration Number			
	,							
			, maine = =					
as my Unite	//our attorney(d States Pater	s) or a it and	gent(s) to prosecute the applicatio Trademark Office connected there	n identifie with.	ed a	above, and to	transact a	Il business in the
Plea	ase recognize	or cha	nge the correspondence address t	for the ab	ove	e-identified ap	plication to):
	-		iated with the above-mentioned Cu			•	•	
OR			ſ					
	The address	assoc	iated with Customer Number:					
OR.								
	Firm or Individual Name	e .						
Addres	ess							
City				Stat	_		17	ip
Count	ťγ			0.00				.k
Teleph	•			Ema	all	·		
l am t	he;			'				15
	Applicant/Invent	tor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).								
			SIGNATURE of Applica	ant or As	sig	nee of Reco	rd	
Signat	ure	Ko	but H. Brunk				Date	23 May 2006
Name							Telephone	919-483-3323
Title a	nd Company							
NOTE: Signatures of all the inventors or assignees of record of the entire Interest or their representative(s) are required. Submit multiple								
□ *Total of forms are submitted.								

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take \$ minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

GW GLOBAL R&D IS

NO. 1082 P. 2/4

Doc Code: PB60121USW

PTO/SB/96 (12-05)

Doc Code: PB60121USW

Approved for use through 07/31/2006. OMB 0661-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CF	R 3.73(b)					
Applicant/Patent Owner: Glaxo Group Limited	<u> </u>					
Application No./Patent No./Control No.: 10/568,399 Filed	/Issue Date:					
Entitled: 7-Azaindole Derivatives as COX2 Inhibitors						
Glaxo Group Limited , a Corporation						
(Name of Assignee) (Type of Assignee, e.g., corporate	ion, partnership, universitý, government agency, étc.)					
states that it is:	v					
1. the assignee of the entire right, title, and interest; or						
2. an assignee of less than the entire right, title and interest The extent (by percentage) of its ownership interest is						
in the patent application/patent identified above by virtue of either:						
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at 017412 , Frame 0957 , or a true copy of the original is attached. OR						
B. A chain of title from the inventor(s), of the patent application/patent identified abort	ve to the current assignee as follows:					
1. From:						
3. From: To:						
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.						
Additional documents in the chain of title are listed on a supplemental sheet.						
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must accordance with 37 CFR Part 3, to record the assignment in the records of the The undersigned (whose title is supplied below) is authorized to act on behalf of the assigne	be submitted to Assignment Division in USPTO. See MPEP 302.08]					
Robert H. Brins						
Signature	23 May 2006 Date					
Robert H. Brink	919-483-3323					
Printed or Typed Name	Telephone number					
Attorney, GlaxoSmithKline						
Title						

This collection of information is required by 37 CFR 3.73(b). The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Power of Attorney

BY THIS POWER OF ATTORNEY given this 20th day of FEBRUARY two thousand and five GLAXO GROUP LIMITED, a company incorporated in England and Wales (Registration No. 305979) and having its registered office at Glaxo Wellcome House, Berkeley Avenue. Greenford, Middlesex, UB6 0NN, England (hereinafter called "the Company"), HEREBY appoints all and any of its Directors, Secretary and Assistant Secretary for the time being, and DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRRELL, MARCUS J. W. DALTON, PETER J. DOLTON, WENDY ANNE FILLER. MICHAEL JOHN STOTT, HUGH BAINFORDE DAWSON, HELEN QUILLIN, CHARLES KINZIG, STEPHEN VENETIANER, THEODORE R. FURMAN, MARY E. MCCARTHY. EDWARD R. GIMMI, CHARLES E. DADSWELL, ROBERT H. BRINK and FRANK P. GRASSLER jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do. perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

- In any country or countries or jurisdiction in any part of the world to make application
 or cause application to be made for the grant or issue or transfer to the Company or
 registration in its name of Intellectual Property Rights and to take all steps necessary
 for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended
 or extended.
- As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
- 3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sublicences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
- 4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the coexistence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
- To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
- For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent,

including trademark and patent agents and attorneys, to act on behalf of the Company.

- To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
- 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
- 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained

AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof GLAXO GROUP LIMITED has caused its Common Seal to be hereunto affixed the day and year first before written

The COMMON SEAL of
GLAXO GROUP LIMITED

was hereto affixed in the presence of:

For and on Behalf of
Edinburgh
Pharmaceutical
Industries
Limited

DIRECTOR

Secretary / Assistant Secretary

